Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 270,000 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 270,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Tuesday, March 10th, Ian Mortimer sold 11,269 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.11, for a total value of $677,379.59.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00.

Xenon Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:XENE traded down $1.57 during mid-day trading on Wednesday, reaching $59.04. The stock had a trading volume of 5,546,191 shares, compared to its average volume of 1,583,794. The firm has a 50 day simple moving average of $43.23 and a two-hundred day simple moving average of $41.69. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95. The firm has a market cap of $4.91 billion, a PE ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the business posted ($0.84) EPS. On average, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Analyst Ratings Changes

XENE has been the topic of several research analyst reports. Needham & Company LLC raised their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley set a $97.00 target price on Xenon Pharmaceuticals in a research note on Monday. Guggenheim restated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday. HC Wainwright raised their price target on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $71.94.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $1,125,000. Caitong International Asset Management Co. Ltd bought a new position in Xenon Pharmaceuticals during the fourth quarter worth about $55,000. Mackenzie Financial Corp bought a new position in Xenon Pharmaceuticals during the fourth quarter worth about $210,000. ADAR1 Capital Management LLC increased its position in Xenon Pharmaceuticals by 7.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock worth $9,142,000 after buying an additional 14,871 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Xenon Pharmaceuticals during the fourth quarter worth approximately $964,000. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.